BioBlast Pharma Ltd. logo

BioBlast Pharma Ltd.

BioBlast Pharma is a publicly traded, clinical-stage biotechnology company (NASDAQ ? ?ORPN?). Developing safe and effective therapies for rare genetic diseases. Bioblast Pharma (NASDAQ: ORPN), is a clinical-stage biotechnology company built on the premise of discovering, developing, and delivering clinically meaningful therapies for patients with rare diseases.

BioBlast Pharma is Tel Aviv, Israel based company founded by Colin Foster, Dr. Dalia Megiddo and Udi Gilboa focuses on building a diverse portfolio of product candidates with the potential to address unmet medical need for incurable rare diseases.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”ORPN” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://bioblastpharma.com
Founded2012
Disease Focus
Development StageClinical
STOCK CODENASDAQ: ORPN
Address
PO Box 318, 6100201
Tel Aviv
Israel
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bioblast-pharma” connections=”true” suffix=””]

BioBlast consists 3 therapeutic technology platforms are Cabaletta, BBrm and mPRT. mPRT is a mitochondrial protein replacement platform that is based on biological fusion proteins used for the treatment of Friedrichs Ataxia and Ornithine Transcarbamylase Deficiency.